AbCellera Biologics Inc. ABCL Proceeds from maturities of marketable securities
Proceeds from maturities of marketable securities at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s proceeds from maturities of marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s proceeds from maturities of marketable securities?
- AbCellera Biologics Inc. (ABCL) reported proceeds from maturities of marketable securities of $143.8M in Q1 2026.
- How has AbCellera Biologics Inc.'s proceeds from maturities of marketable securities changed year-over-year?
- AbCellera Biologics Inc.'s proceeds from maturities of marketable securities decreased by 24.3% year-over-year, from $190.03M to $143.8M.
- What is the long-term trend for AbCellera Biologics Inc.'s proceeds from maturities of marketable securities?
- Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s proceeds from maturities of marketable securities has grown at a -25.5% compound annual growth rate (CAGR), from $910.94M to $506.07M.
- What does proceeds from maturities of marketable securities mean?
- This metric represents the cash inflows resulting from the sale or maturity of short-term financial investments. It demonstrates the company's ability to convert its treasury holdings back into cash to fund operations or other strategic needs.